Keywords: |
cancer chemotherapy; survival rate; overall survival; lenalidomide; mortality; cancer recurrence; rituximab; metabolism; cancer immunotherapy; progression free survival; editorial; autologous stem cell transplantation; stem cell transplantation; hematopoietic stem cell transplantation; diagnostic imaging; biopsy; risk assessment; chimeric antigen receptor; anthracycline; follicular lymphoma; lymphoma, follicular; transplantation, autologous; primary health care; autotransplantation; clinical outcome; procedures; nivolumab; humans; human; positron emission tomography-computed tomography; positron emission tomography computed tomography; tisagenlecleucel t; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel
|